According to a new report, published by KBV research, The Global Controlled Release Drug Delivery Market size is expected to reach $106.3 billion by 2030, rising at a market growth of 10.4% CAGR during the forecast period.
The Activation-modulated Drug Delivery Systems segment is showcasing a CAGR of 10.1% during (2023 - 2030). By restricting drug exposure to healthy organs and tissues, activation-modulated drug delivery devices reduce systemic toxicity. Some of the most common and prevalent activation-modulated drug delivery systems include osmotic pressure activated, hydrodynamic pressure activated, vapor pressure activated, mechanically activated, and magnetically activated. Therapeutic concentrations are reached at the location of action while limiting off-target effects owing to the regulated release and focused administration of medicines. This can lessen negative side effects and increase the safety profile of medications.
The Targeted Delivery segment is leading the Global Controlled Release Drug Delivery Market by Technology in 2022, thereby, achieving a market value of $23.9 billion by 2030. Targeted delivery provides a preferred point of action along with helping in keeping medications away from areas where they might cause drug toxicity. As a result of these systems' higher bioavailability and localization provided by targeted technologies, absorption is better, circulating medication levels fluctuate less, and side effects are less likely to occur. It is a widely used and recommended drug delivery method, and hence will continue to grow in demand throughout the forecast period.
The Injectable segment has shown the high growth rate of 11.3% during (2023 - 2030). Due to their large product variety and widespread application in treating numerous diseases, demand for injectables is expanding. Long acting injectables are chosen over traditional delivery forms because they have several benefits, such as a predictable drug release profile over a set period, improved patient compliance, enhanced systemic availability of drugs, and simple application. These benefits also aid in a consequent overall decrease in medical costs.
The North America region dominated the Global Controlled Release Drug Delivery Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $42.8 billion by 2030. The Europe market is poised to grow at a CAGR of 10.2% during (2023 - 2030). Additionally, The Asia Pacific market would witness a CAGR of 11.2% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/controlled-release-drug-delivery-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Johnson & Johnson, Merck & Co., Inc., Alkermes PLC, Pfizer, Inc., Assertio Holdings, Inc. (Assertio Therapeutics, Inc.), Lonza Group AG (Capsugel), Colorcon, Inc. (BPSI Holdings LLC.), Corium, LLC (Gurnet Point Capital), Adare Pharma Solutions, and Coating Place, Inc.
By Release Mechanism
By Technology
By Application
By Geography
Companies Profiled
Unique Offerings 
